Tesamorelin is an FDA-approved prescription peptide that tells your pituitary gland to make more growth hormone in a natural, pulsatile way. It was approved specifically to reduce dangerous belly fat buildup in HIV patients. Research also suggests it may help with brain function in older adults. Because it raises growth hormone and IGF-1, it requires medical supervision and monitoring.
How it works
Tesamorelin works by gently nudging your body's own "control center" (a small gland in your brain called the pituitary) to make and release more of your natural growth hormone—instead of putting growth hormone into your body from the outside. Because it works with your body's normal signals, it keeps your natural on/off system in balance rather than overriding it. That extra growth hormone helps your body burn fat, and it targets the deeper belly fat around your organs in particular, which is the harder-to-lose kind. It can also trim fat around your midsection and make modest improvements to your cholesterol numbers. As growth hormone goes up, a related marker called IGF-1 rises alongside it.
For the nerds:
Tesamorelin binds to GHRH receptors in the anterior pituitary, stimulating the synthesis and pulsatile release of endogenous growth hormone (GH). This preserves the physiologic feedback regulation of the GH/IGF-1 axis, unlike exogenous GH administration. Elevated GH drives lipolysis preferentially in visceral adipose tissue, reduces trunk fat accumulation, and modestly improves lipid profiles. IGF-1 levels rise proportionally.
What the evidence shows
Overall strength of the evidence, by our read: Strong Evidence. Some of what that rests on:
Tesamorelin reduces visceral adiposity in HIV-infected patients: phase III RCT (2010) — Two pivotal phase III RCTs demonstrated that tesamorelin 2 mg/day reduced visceral adipose tissue (VAT) by approximately 15–18% from baseline over 26 weeks versus placebo in HIV lipodystrophy.
Tesamorelin and cognitive function in older adults with mild cognitive impairment: an RCT (2012) — Tesamorelin 1 mg/day for 20 weeks improved executive function and verbal memory scores in older adults with mild cognitive impairment compared to placebo, with IGF-1 elevation correlating with cognitive benefit.
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV (2014) — Tesamorelin significantly reduced liver fat content (measured by MRS) and improved liver enzymes in HIV-infected adults with NAFLD over 12 months.
Preliminary or early findings are not the same as proof. Any use beyond a peptide's FDA-approved labeling (where one exists) is described here for educational purposes only and is not a recommendation.
Safety profile
Injection site reactions, fluid retention, arthralgia, myalgia, and peripheral edema are most common. May worsen glucose tolerance and insulin resistance. Contraindicated in active malignancy, pituitary tumor, pregnancy. Potential to increase IGF-1 above normal range with chronic use.
Reasons to avoid it, or to talk to a clinician first:
Active malignancy (FDA contraindication — tesamorelin stimulates GH which can promote tumor growth)
Disruption of the hypothalamic-pituitary axis from hypophysectomy, hypopituitarism, or pituitary tumor/surgery (FDA contraindication)
Pregnancy (FDA contraindication — Category X)
Known hypersensitivity to tesamorelin or mannitol (FDA contraindication)
Breastfeeding
This is not a complete safety list and should discussion with your physician before trying Tesamorelin.
Questions worth bringing to a clinician
Do I meet criteria for FDA-approved tesamorelin use (HIV-associated lipodystrophy), or would this be off-label?
What are the risks of elevating IGF-1 levels, particularly given any personal or family history of cancer?
How does tesamorelin differ from exogenous growth hormone in terms of safety?
New research, translated
A Two-part Study Investigating the Effect of the X39 Patch on Circulating Blood Levels of GHK and GHK-Cu in a Healthy Adult Population
2027-01 · INTERVENTIONAL · GHK-Cu
Scientists are starting a new study to test a skin patch called X39, which is made by a company named LifeWave. They want to find out if wearing the patch raises the blood levels of two natural copper-peptides called GHK and GHK-Cu, which the body uses to help repair itself. About 100 healthy adults age 35 and older will wear either the real patch or a placebo patch, and researchers will check their blood on Day 2 and Day 8 to see if the levels change. This will help show whether the patch really does what the company says, compared to wearing no active patch at all.
The study is sponsored by LifeWave itself (the patch maker), which is worth noting. This research hasn't started yet, so there are no results to report at this time.
Effect of Melatonin in Peripartum Cardiomyopathy
2026-12-20 · INTERVENTIONAL · melatonin
Doctors are planning a new study to see if melatonin—the natural sleep hormone your body makes—can help women whose hearts became weak during or right after pregnancy, a serious problem called peripartum cardiomyopathy. Along with their normal heart medicine, some women will also take melatonin or a mineral called selenium, while others take a "dummy" pill, so the doctors can compare them fairly. Over three months, the team will use heart ultrasounds to check how well each woman's heart is pumping and healing, and they'll test her blood for signs of swelling and inflammation. They hope melatonin's calming, protective effects on the body will help these women's hearts get stronger and recover faster.
This research hasn't started yet, so there are no results to report at this time.
A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Oral NA-931, Alone or in Addition to Open Label Subcutaneous Tirzepatide , to Investigate the Efficacy and Safety in Overweight or Obese Men and Women
2026-08-15 · INTERVENTIONAL · tirzepatide
Researchers are planning a study to test a new weight-loss pill called NA-931, used either by itself or together with tirzepatide, the injected medicine many people already know for weight loss. About 224 adults who are overweight or obese will take the pill, the shot, both, or placebos so doctors can fairly compare how well each one works over roughly a year. Besides tracking pounds lost, the team will use special body scans to check something important: whether people keep their muscle while losing fat, instead of losing both. The hope is that adding NA-931 helps people lose more fat, protect their muscle, and have fewer side effects than the shot alone.
This is an early study, so we won't know the results for a couple of years.
What readers are asking
Topics we'll be tracking:
Off-Trial: Real-World Weight Loss on Tirzepatide and Semaglutide
AlfaDAX-Derived ActRIIA/B Antibody with Semaglutide Enhances Fat Loss and Improves Weight-Loss Quality in DIO Mice
Efficacy and safety of semaglutide for obesity and hyperphagia in adults with Prader-Willi syndrome
Peptide Disclaimer
Tesamorelin (Egrifta, Egrifta SV) is an FDA-approved prescription medication indicated for: HIV-associated lipodystrophy (abdominal fat). Any discussion of uses beyond the FDA-approved labeling is for educational purposes only and does not constitute a recommendation for off-label use. Tesamorelin is a prescription medication that requires a valid prescription from a licensed healthcare provider. Do not attempt to obtain or use this medication without proper medical supervision.
Medical disclaimer
This letter is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment, and no provider-patient relationship is created by reading it. Peptides and medications discussed may not be FDA-approved for the uses described. Always consult your healthcare provider before making any health decision. Read our full medical disclaimer.